Area of research
Pulmonary and Respiratory Medicine · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Pulmonary Hypertension Research and Treatments, Cardiovascular Function and Risk Factors, Chronic Obstructive Pulmonary Disease (COPD) Research, and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis.
Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death
Lysosomal dysfunction and inflammatory sterol metabolism in pulmonary arterial hypertension
A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis
Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies
Dysregulated Tricarboxylic Acid Cycle Metabolism Is Associated With Right Ventricular Maladaptation in Pulmonary Vascular Disease
Pericardial effusion in sotatercept phase 3 trials: insights from STELLAR and ZENITH
SPECTRA Phase 2b Study: Impact of Sotatercept on Exercise Tolerance and Right Ventricular Function in Pulmonary Arterial Hypertension
Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE study
Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension
Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial
Sleep-Related Hypoxia, Right Ventricular Dysfunction, and Survival in Patients With Group 1 Pulmonary Arterial Hypertension
Survival analysis from the INCREASE study in PH-ILD: evaluating the impact of treatment crossover on overall mortality
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension
Clinical Characteristics and Transplant-Free Survival Across the Spectrum of Pulmonary Vascular Disease
Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes
Sotatercept for the Treatment of Pulmonary Arterial Hypertension
Persistent Exertional Intolerance After COVID-19
Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial
Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease
BOLA (BolA Family Member 3) Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension
Dynamic right ventricular–pulmonary arterial uncoupling during maximum incremental exercise in exercise pulmonary hypertension and pulmonary arterial hypertension
Long‐term results of the DelIVery for Pulmonary Arterial Hypertension trial
Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure
Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension
Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System
Exercise intolerance in pulmonary hypertension: mechanism, evaluation and clinical implications
Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit
Genetic and hypoxic alterations of the microRNA‐210‐ISCU1/2 axis promote iron–sulfur deficiency and pulmonary hypertension